Lori Leslie, MD, Discusses CAR T-cell therapy and DLBCL

Video

Lori Leslie, MD, of the John Theurer Cancer Center, sat down to discuss the relationship between chimeric antigen receptor (CAR) T-cell therapy and diffuse large B cell lymphoma (DLBCL) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.

Transcription:

So, I think in DLBCL right now CAR T-cell (therapy) is very exciting (and) really has revolutionized how we treat patients with relapsed/refractory disease. There’s some very interesting CAR T information being presented at ASH. 

I’m interested in the mechanisms of resistance. So even though CAR T is an effective therapy, long-term remissions overall are about 40%. So is it the loss of CD19, different CD19 epitopes, that leads to (patients’) progressions or lack of responses (that) is really changing development of CAR T(-cell therapy). 

How do we combine therapies? How do we create different targets? Maybe dual specific targets for CAR T(-cell therapy) to help increase the overall efficacy of long-term (complete responses) and potentially cure patients.

Related Videos
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
J. Andrew Livingston, MD
Shankar Musunuri, PhD
© 2023 MJH Life Sciences

All rights reserved.